The Food and Drug Administration said it approved Akeega with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by an FDA-approved test. Akeega is developed by Johnson & Johnson’s Janssen Biotech.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $197 from $190 at Morgan Stanley
- Johnson & Johnson price target raised to $230 from $209 at RBC Capital
- Johnson & Johnson price target raised to $232 from $215 at Citi
- Johnson & Johnson price target raised to $240 from $215 at HSBC
- Cautious Hold Rating for Johnson & Johnson Amid Promising Clinical Results and Competitive Challenges